← SynDRA
BRINZOLAMIDE
SynDRA canonical compound SYN0006486 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CA7 |
|---|
| Mechanism of action | Carbonic anhydrase inhibitor |
|---|
| Indication | glaucoma | intraocular pressure | ocular hypertension |
|---|
| Disease area | ophthalmology |
|---|
All known targets
- CA2
- CA4
- CA7
- CA1
- CA12
- CA14
- CA5A
- CA
- Ca13
- mtcA1
- cynT
- ca1
Mechanisms of action (all sources)
- Carbonic anhydrase inhibitor
- CA2 INHIBITOR
- Carbonic anhydrase II inhibitor
- CA4 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- BAZ2B
- CA3
- CBX1
- HDAC6
- PLAUR
- SAMHD1
- TDP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CAH12
- CAH14
- CAH7
- CFTR
- CYP21A2
Drug classes
- Carbonic Anhydrase Inhibitors
- Carbonic Anhydrase Inhibitor
- Enzyme Inhibitors
ATC classes
- S01E · ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Cross-references
Synonyms
- AZOPT
- Azopt
- SIMBRINZA
- AL-4862
- azopt
- Brinzolamida
- NSC-760050
- Brinzolamide component of azarga
- Brinzolamide component of simbrinza
- Birnzolamide
- Alcon brand of brinzolamide
- Allphar brand of brinzolamide
- Brinzolamide [USAN]
- AL04862
- BZ1
- Azopt (TN)
- Brinzolamide (BRZ)
- Brinzolamide (JAN/USP/INN)
- brinzolamide (usp impurity)
- SIMBRINZA COMPONENT BRINZOLAMIDE
- brinzolamide (usp monograph)
- NSC 760050
- brinzolamide (usp-rs)
- AL 4862
- AZARGA COMPONENT BRINZOLAMIDE
- CHEBI:3176
- DTXCID4025531
- brinzolamidum
- RefChem:57193
- S01EC04
- C12H21N3O5S3
- MFCD08067749
- 3znc
- NCGC00016979-01
- Brinzolamide [USAN:USP:INN:BAN]
- UNII-9451Z89515
- CAS-138890-62-7
Reported adverse events
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
Look up BRINZOLAMIDE in the interactive SynDRA portal →